Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Fortress Biotech, Inc. before investing.

In this article, we go over a few key elements for understanding Fortress Biotech, Inc.’s stock price such as:

• Fortress Biotech, Inc.’s current stock price and volume
• Why Fortress Biotech, Inc.’s stock price changed recently
• Upgrades and downgrades for FBIO from analysts
• FBIO’s stock price momentum as measured by its relative strength

About Fortress Biotech, Inc. (FBIO)

Before we jump into Fortress Biotech, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Want to learn more about Fortress Biotech, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Fortress Biotech, Inc..

Fortress Biotech, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Fortress Biotech, Inc.’s stock price was $3.130.

Fortress Biotech, Inc. is down 4.86% from its previous closing price of $3.290.

During the last market session, Fortress Biotech, Inc.’s stock traded between $3.080 and $3.280. Currently, there are approximately 31.54 million shares outstanding for Fortress Biotech, Inc..

Fortress Biotech, Inc.’s price-earnings (P/E) ratio is currently at 0.8, which is low compared to the Biotechnology industry median of 19. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Fortress Biotech, Inc. Stock Price History

Fortress Biotech, Inc.’s (FBIO) price is currently up 2.29% so far this month.

During the month of July, Fortress Biotech, Inc.’s stock price has reached a high of $3.840 and a low of $2.873.

Over the last year, Fortress Biotech, Inc. has hit prices as high as $4.530 and as low as $1.770. Year to date, Fortress Biotech, Inc.’s stock is down 14.48%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Fortress Biotech, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Fortress Biotech, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Fortress Biotech, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Fortress Biotech, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Fortress Biotech, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Fortress Biotech, Inc. (FBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Fortress Biotech, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Fortress Biotech, Inc. has a weighted four-quarter relative price strength of 15.77%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Fortress Biotech, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Fortress Biotech, Inc. Stock Price: Bottom Line

As of July 31, 2026, Fortress Biotech, Inc.’s stock price is $3.130, which is down 4.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Fortress Biotech, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.